Ars Pharmaceuticals, Inc.
A maker of neffy, the first FDA-approved needle-free nasal spray for emergency treatment of severe allergic reactions (anaphylaxis), replacing the familiar auto-injector shot. Founded in 2015 by Richard Lowenthal, Dr. Sarina Tanimoto, and Dr. Robert Bell, the company's name is understood to reflect its focus on the allergic reaction system. neffy marked the first significant innovation in epinephrine delivery in over 35 years, offering a needle-free option for people who fear or avoid injectors.
Granted 30.0K · Sold 166.4K
Sold 3.4K
Granted 25.0K · Sold 25.0K
Granted 21.8K · Sold 21.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Shah PratikDirector · 2 transactions | -5.2% | 4.57M | — | — | — |
| Chakma JustinChief Business Officer · 3 transactions | +1.7% | 166.4K | 30.0K | — | 166.4K |
| Fitzpatrick Alexander AChief Legal Officer · 1 transaction | +1.4% | 90.9K | — | — | 3.4K |
| Karas EricChief Commercial Officer · 2 transactions | +18% | 12.2K | 25.0K | — | 25.0K |
| Dorsey BrianChief Operating Officer · 2 transactions | +79.1% | 10.8K | 21.8K | — | 21.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -216.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.